Virogin Biotech Announces Upcoming Presentation at the AACR Annual Meeting
VANCOUVER, BC – Virogin Biotech today announced that it will present results from preclinical studies evaluating the effects of pre-existing HSV-1 immunity on anti-cancer efficacy of VG161 – the company’s… Read More




